First Key Data From World's Largest Heart Failure Registry to be Presented
At 2003 American Heart Association Scientific Sessions in Orlando
FREMONT, Calif., Nov. 6 /PRNewswire/ -- Scios, Inc. today announced the
achievement of a new target milestone with the registration of 100,000 patient
cases from more than 275 hospitals into ADHERE(TM) (Acute Decompensated Heart
Failure National Registry), the largest most extensive registry of acute heart
failure patient cases in the world. Underscoring the growing importance of
ADHERE data in improving acute heart failure treatment, key studies that
utilize registry data and outline methods to increase quality of care will be
presented during the American Heart Association's Scientific Sessions 2003 in
Orlando next week.
-- Gregg C. Fonarow, M.D., of the UCLA Medical Center in Los Angeles will
present an analysis of ADHERE data evaluating the performance and variation in
measurement indicators that have been developed to evaluate quality of care in
hospitalized acute heart failure (AHF) patients. This study, entitled
Variation in Heart Failure Quality of Care Indicators Among U.S. Hospitals:
Analysis of 230 Hospitals in ADHERE (Abstract # 6860), will take place on
Monday, November 10th from 9:30 - 11:00 a.m. in Hall A.
-- Also on Wednesday, November 12th, Maria Rosa Costanzo, M.D., of Midwest
Heart Specialists in Naperville, IL will present an analysis of ADHERE data
investigating the differential effects of IV vasoactive agents versus
inotropes on in-hospital acute heart failure patient mortality. This
presentation, entitled Evaluation of In-Hospital Mortality in Patients Treated
for Acute Heart Failure Within the First 24 Hours with Nesiritide vs. Other
Vasoactive or Inotropic Agents (Abstract # 15680), will take place from
2:00 - 4:45 p.m. in Hall F (1&2).
-- An additional study of ADHERE data by Dr. Fonarow will be presented on
Wednesday, November 12th from 2:00 - 5:00 p.m. in Room 240. This analysis,
entitled Risk Stratification for In-Hospital Mortality in Heart Failure Using
Classification and Regression Tree (CART) Methodology: Analysis of 33,046
Patients in ADHERE (Abstract # 6826) uses ADHERE data to determine whether a
straightforward clinical method can be put in place to quickly and easily
identify acute decompensated heart failure patients who are at risk for
in-hospital mortality.
-- Kirkwood F. Adams, Jr. of the University of North Carolina, Chapel
Hill, presents an analysis of ADHERE data on Wednesday, November 12th,
evaluating the effectiveness of inotrope use in patients with preserved
systolic function. This study, entitled Inotrope Use and Negative Outcomes in
Treatment of Acute Heart Failure in Patients with Preserved Systolic Function:
Data from the ADHERE(TM) Database (Abstract # 5716) takes place from
2:00 - 4:45 p.m. in Hall F (1&2).
About ADHERE
ADHERE is a first-of-its-kind national registry designed to improve the
quality of acute heart failure patient care. Sponsored by Scios and overseen
by an independent scientific advisory committee of nationally recognized heart
failure experts, ADHERE prospectively collects observational data on the
medical management of patients hospitalized with acute heart failure across
the United States. Clinicians use data from ADHERE to investigate how to
improve acute heart failure treatment.
The ADHERE Registry Core Module was launched in October 2001. It is a
multicenter, observational, open-label registry of the management of patients
treated in the hospital for acutely decompensated congestive heart failure
(CHF). The Registry is a large clinical database that utilizes information
collected from acute care hospitals across the United States to help the
medical community better understand acute CHF, improve its management and
enhance quality of care. Data regarding current management and treatment
trends is collected from The Registry and analyzed on a quarterly basis.
These data and insights can be used by individual hospitals to develop
guidelines and protocols and increase the use of evidence-based therapies to
improve the standard of care among heart failure patients, and, potentially
reduce costs.
To learn more about the ADHERE Registry, call 1-866-616-2993, or e-mail
adhereinfo@sciosinc.com, or visit http://www.adhereregistry.com.
New Outpatient Longitudinal Model
Last April, ADHERE was expanded to include the longitudinal module (LM)
for tracking more than 2000 patients in the outpatient setting for two years.
Kirkwood F. Adams, Jr., M.D., Associate Professor of Medicine and
Radiology, Division of Cardiology, University of North Carolina, who presented
information about the ADHERE LM Registry indicated that it provides a unique
opportunity to gather important data on many aspects of high-risk patients
with advanced heart failure and could answer some very important questions
about optimal outpatient treatment strategies. For example, he said much more
needed to be learned about the prognostic role of renal insufficiency and
whether standard clinical characteristics can provide a user-friendly guide to
risk using a congestive heart failure (CHF) risk score.
About Acute Heart Failure
During an episode of acute heart failure, the heart's inability to
circulate blood adequately throughout the body worsens to the point where
hospitalization is necessary to stabilize the patient's condition. A sudden
increase in salt in a person's diet, a patient's failure to take prescribed
oral medications or the development of a new heart problem can cause these
acute episodes. Virtually all congestive heart failure patients will
experience at least one acute episode, severe enough that only intravenous
medications administered in the hospital can improve a patient's condition.
More than one million hospitalizations of patients with acute congestive
heart failure as the primary diagnosis occur in the United States each year.
This translates into a health-care system cost of $15 billion. Another
two million Americans are hospitalized annually with acute congestive heart
failure as a secondary diagnosis. Congestive heart failure accounts for the
greatest number of hospitalizations of patients over the age of 65.
Scios Inc.
Scios, a Johnson & Johnson company, is a biopharmaceutical company
headquartered in Fremont, California. Scios is developing novel treatments
for cardiovascular and inflammatory disease. The Company's disease-based
technology platform integrates expertise in protein biology with computational
and medicinal chemistry to identify novel targets and rationally design small
molecule compounds for markets with unmet medical needs.
SOURCE Scios, Inc.
 back to top
Related links:
http://www.sciosinc.com
CONTACT:
Chris L. Bing of Scios, Inc.,
+1-415-710-9445; or Karin Bauer Aranaz of WeissCom Partners,
Inc., +1-415-859-3414, for Scios, Inc.
|
